Duality Biologics has caught the eye of another global biotech. Months after inking a deal with BioNTech, the antibody-drug conjugate (ADC) specialist has granted BeiGene an option on a preclinical asset in return for a financial package worth up to $1.3 billion.

二元生物制剂引起了另一个全球生物技术的关注。在与BioNTech达成协议数月后，抗体-药物偶联物（ADC）专家已授予BeiGene对临床前资产的选择权，以换取价值高达13亿美元的财务组合。

BioNTech helped put the Shanghai-based DualityBio on the map in April by paying $170 million upfront for the rights to two ADCs, including a HER2-directed rival to AstraZeneca and Daiichi Sankyo’s Enhertu. Now, DualityBio has found a taker for another candidate in a pipeline of programs designed to be best or first in class..

BioNTech于4月帮助将上海DualityBio放在地图上，向两个ADC支付1.7亿美元的权利，其中包括与AstraZeneca和Daiichi Sankyo的Enhertu的HER2竞争对手。现在，DualityBio在一系列设计最佳或一流的课程中找到了另一位候选人的看护人。。

BeiGene has taken the other side of the deal, but publicly available details are scant at this stage. What we know is that BeiGene is paying an upfront fee of undisclosed size for an exclusive option for a global license to an investigational, preclinical ADC therapy for patients with select solid tumors..

BeiGene采取了另一方面的交易，但现阶段公众可获得的细节很少。我们知道的是，BeiGene正在支付未公开大小的预付费，作为选择实体瘤患者的研究性临床前ADC治疗的全球许可的独家选择。。

DualityBio will receive an option fee, again of publicly undisclosed size, if BeiGene decides to pick up the asset and is in line to receive development, regulatory and commercial milestones that could swell the size of the deal to $1.3 billion. BeiGene will hold global clinical, manufacturing and commercial rights if it exercises its option, and DualityBio will handle all research through IND-enabling studies..

如果BeiGene决定收购该资产并符合接受开发，监管和商业里程碑的要求，DualityBio将获得期权费，再次公开未披露规模，这可能会使交易规模扩大至13亿美元。如果BeiGene行使其选择权，BeiGene将拥有全球临床，制造和商业权利，DualityBio将通过IND启用研究处理所有研究。。

“Through this strategic partnership with DualityBio, we are well positioned to advance this asset globally alongside our initial internally discovered ADC assets with our end-to-end ADC manufacturing capabilities,” Lai Wang, Ph.D., global head of R&D at BeiGene, said in a statement.

BeiGene全球研发主管Lai Wang博士说：“通过与DualityBio的战略合作关系，我们有能力将这项资产与我们最初内部发现的ADC资产以及我们的端到端ADC制造能力一起推向全球。”在一份声明中说。

BeiGene previously bought into an ADC in 2019 when it secured rights to Seagen’s SEA-CD70 in Asia, Australia and New Zealand. CD70 is expressed on malignant myeloid blasts but absent from healthy hematopoietic progenitor cells, leading Seagen to identify ADCs directed at the target as a way to treat myelodysplastic syndrome and acute myeloid leukemia..

BeiGene之前于2019年收购了Seagen的SEA-CD70在亚洲，澳大利亚和新西兰的权利。CD70在恶性骨髓原始细胞上表达，但在健康的造血祖细胞中不存在，导致Seagen鉴定针对靶标的ADC作为治疗骨髓增生异常综合征和急性髓性白血病的方法。。

DualityBio and BeiGene are yet to disclose the target of their partnered program. Interest in DualityBio is underpinned by its work to expand the therapeutic windows of ADCs, which has seen it use technology to try to improve stability and slow deconjugation.

DualityBio和BeiGene尚未披露其合作计划的目标。对DualityBio的兴趣得益于其扩展ADC治疗窗口的工作，该工作已经看到它使用技术来尝试改善稳定性和减缓去共轭。